MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Snowdon, Inc., today announced that it has been awarded a new three-year contract from the Department of Defense (DoD) Program, Transformational Medical Technologies (TMT) for the discovery and preclinical development of novel medical treatments to combat biowarfare pathogens. Snowdon may receive up to $8.2 million in support of development efforts under this new Defense Threat Reduction Agency (DTRA) contract.
Snowdon is partnering with two centers of excellence at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS). The Center for Emerging Pathogens in the Department of Medicine, under the direction of Dr. Nancy Connell, will test Snowdon’s drug candidates on specific biowarfare pathogens. The Center maintains high-level biosafety containment facilities for this purpose. Snowdon will also be assisted by the newly opened Regional Biocontainment Laboratory of UMDNJ under the direction of Dr. David Perlin, Director of the Public Health Research Institute (PHRI).
Snowdon has recently expanded its research and development space and facilities in the Princeton Research Center (Monmouth Junction, NJ) and has hired additional scientific staff and technical personnel. This DTRA contract will complement Snowdon’s ongoing activities in the development of novel treatments for pain, nervous system disorders, and other infectious diseases.
About Snowdon Inc.
Snowdon, Inc., is a biopharmaceutical company that specializes in the discovery and development of novel small-molecule therapeutics for the treatment of pain, infectious diseases and nervous system disorders. By applying its proprietary E-Prospector platform technology together with its expertise in medicinal chemistry, pharmacology, and computational drug design, Snowdon reduces the time, cost, and risk of drug discovery. Founded in 2007 by William J. Welsh, PhD, the Norman H. Edelman Professor in the Department of Pharmacology at UMDNJ-Robert Wood Johnson Medical School, Snowdon was established through an equity investment by the Foundation Venture Capital Group (FVCG) LLC together with grants from the New Jersey Commission on Science & Technology and the National Institutes of Health (NIH). For more information, visit the company’s website at www.snowdonpharma.com.